A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Phase 3 Recruiting 60 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Timeline

Start: 2025-03-13
Primary completion: 2030-03-06
Completion: 2031-03-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	—	—

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Summary

Timeline

Drugs

Indications